The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

New state-of-the-art facility in Plainville, Mass., to manufacture materials central to production of gene-based therapeutics “Plainville is an impressive addition to our pharma services network as we ...

Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global viral vectors & plasmid DNA manufacturing market was valued at 4.21 billion in 2024 and is expected to reach US$ 20.30 billion by 2033, growing at ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and ...

Increase in funding for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of the global viral ...